Concepedia

Author

Bart Barlogie

University of Arkansas for Medical SciencesORCID

Also Known As

Ashraf Badros, B Barlogie, B M Barlogie, B. Barlogie, BART BARLOGIE, Barlogie Bart, Barlogie, Bart, Bart Barlogie, Bart Barlogie (234822), Dan Grandér

1.2K

Publications

75.8K

Citations

137

H-Index

188

Concepts

All Affiliations

University of Arkansas for Medical SciencesCancer Research And BiostatisticsThe University of Texas MD Anderson Cancer CenterMayo Clinic in ArizonaDana-Farber Cancer Institute
BB

About

Bart Barlogie is an author at University of Arkansas for Medical Sciences specializing in medicine, hematology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

57

136

13.5K

2

Health Sciences

30

46

4.2K

3

Engineering

4

4

118

4

Natural Sciences

1

1

17

5

Public Health

1

1

71

Bart Barlogie

×

437

Publications

65.6K

Citations

132

H-Index

YearCitations

International Staging System for Multiple Myeloma

Philip R. Greipp, Jesús F. San Miguel, Brian G.M. Durie,

Journal of Clinical Oncology

2005

2.9K

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Paul G. Richardson, Bart Barlogie, James R. Berenson,

New England Journal of Medicine

2003

2.6K

International uniform response criteria for multiple myeloma

Brian G.M. Durie, J-L Harousseau, Jesús F. San Miguel,

Leukemia

2006

2.6K

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Seema Singhal, Jayesh Mehta, Raman Desikan,

New England Journal of Medicine

1999

2.6K

The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma

Erming Tian, Fenghuang Zhan, Ronald C. Walker,

New England Journal of Medicine

2003

1.5K

The molecular classification of multiple myeloma

Fenghuang Zhan, Yongsheng Huang, Simona Colla,

Blood

2006

1.1K

Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma

Christina M. Annunziata, R. Eric Davis, Yulia N. Demchenko,

Cancer Cell

2007

929

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1

John D. Shaughnessy, Fenghuang Zhan, Bart Burington,

Blood

2006

904

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

Brian G.M. Durie, Antje Hoering, Muneer H. Abidi,

The Lancet

2016

868

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

Sundar Jagannath, Bart Barlogie, James R. Berenson,

British Journal of Haematology

2004

739

Page 1